Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease

Long-acting bronchodilators have been shown to improve multiple clinical outcomes in chronic obstructive pulmonary disease (COPD) including lung function, symptoms, dyspnea, quality of life, and exacerbations. Indacaterol is a novel, inhaled, long-acting β2-agonist providing 24-hour bronchodilation with once-daily dosing. It is currently approved for the maintenance treatment of COPD to be admi...

Pharmacological characterisation of indacaterol, a novel once-daily inhaled β2-adrenoceptor agonist, on small airways in human and rat precision-cut lung slices

Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo- controlled comparison

200 words] Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist bronchodilator, recently approved in Europe for the treatment of COPD. This study set out to investigate the efficacy and safety of indacaterol compared with placebo and the twice-daily β2-agonist, salmeterol, as an active control. Patients with moderate-to-severe COPD were randomized to 6 months’ double-blind ...

The Preclinical Pharmacology of Indacaterol

The preclinical pharmacological profile of indacaterol, a novel, chirally pure inhaled beta(2) adrenoceptor agonist, is described in this chapter. In various in vitro systems, indacaterol is close to a full agonist at the human β2-adrenoceptor with nanomolar potency. In isolated superfused human and guinea pig trachea, indacaterol has a fast onset of and a long duration of action. In the consci...

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review

Bronchodilators are central drugs in the management of patients with chronic obstructive pulmonary disease (COPD). Indacaterol was the first agent of the novel family of very long-acting β2-agonists to be used as an inhaled bronchodilator for COPD and provides 24-hour therapeutic action, thus allowing once-daily administration. Data from clinical trials show that indacaterol has a bronchodilato...